Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 470-476

  Choi, Yun Jung ^a   Roberts, Brian K ^a,c   Wang, Xueyan ^a   Geaney, J Casey ^b   Naim, Sue ^a   Wojnoonski, Kathleen ^b   Karpf, David B ^a,c   Krauss, Ronald M ^b  

^a Metabolex Inc   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HDL; LDL; Lipoprotein subfractions; Peroxisome proliferator activated receptor delta; Small dense LDL; Triglyceride; VLDL

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; MBX 8025; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACETIC ACIDS; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PARTICLE SIZE; PPAR GAMMA; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84855936714     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.029     Document Type: Article

References (30)

1. Oliver W.R., Shenk J.L., Snaith M.R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001, 98:5306-5311.
2. Wallace J.M., Schwarz M., Coward P., et al. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005, 46:1009-1016.
3. Tanaka T., Yamamoto J., Iwasaki S., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003, 100:15924-15929.
4. Wang Y.X., Lee C.H., Tiep S., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
5. Wang Y.X., Zhang C.L., Yu R.T., et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004, 2:e294.
6. Leibowitz M.D., Fievet C., Hennuyer N., et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000, 473:333-336.
7. Briand F., Naik S.U., Fuki I., et al. Both the peroxisome proliferator-activated receptor delta agonist, W0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci 2009, 2:127-133.
8. Pelton P. GW-501516 GlaxoSmithKline/Ligand. Curr Opin Investig Drugs 2006, 7:360-370.
9. Sprecher D.L., Massien C., Pearce G., et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007, 27:359-365.
10. Riserus U., Sprecher D., Johnson T., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
11. Bays H.E., Schwartz S., Littlejohn T., et al. MBX-8025, A novel peroxisome proliferator receptor-δ agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011, 96:2889-2897.
12. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363-1379.
13. Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 2010, 21:305-311.
14. Caulfield M.P., Li S., Lee G., et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem 2008, 54:1307-1316.
15. Musunuru K., Orho-Melander M., Caulfield M.P., et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 2009, 29:1975-1980.
16. Farnier M., Perevozskaya I., Taggart W.V., et al. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008, 49:2641-2647.
17. Frost R.J., Otto C., Geiss H.C., et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001, 87:44-48.
18. Rizzo M., Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007, 23:1103-1111.
19. Farnier M., Roth E., Gil-Extremera B., et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007, 153(335):e1-e8.
20. Haubenwallner S., Essenburg A.D., Barnett B.C., et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995, 36:2541-2551.
21. Staels B., Vu-Dac N., Kosykh V.A., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995, 95:705-712.
22. Karalis D.G., Ishisaka D.Y., Luo D., et al. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol 2007, 100:445-449.
23. Kappelle P.J., Dallinga-Thie G.M., Dullaart R.P. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochim Biophys Acta 2010, 1801:89-94.
24. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003, 31:1066-1069.
25. Watts G.F., Naoumova R.P., Kelly J.M., et al. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997, 273:E462-E470.
26. Akiyama T.E., Lambert G., Nicol C.J., et al. Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J Biol Chem 2004, 279:20874-20881.
27. Roberts L.D., Hassall D.G., Winegar D.A., et al. Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor delta from Peroxisome proliferator-activated receptor gamma in the ob/ob mouse. Genome Med 2009, 1:115.
28. Staiger H., Haas C., Machann J., et al. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes 2009, 58:579-589.
29. Adiels M., Taskinen M.R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
30. Fabbrini E., Magkos F., Mohammed B.S., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009, 106:15430-15435.